Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Novartis

    Tag: Novartis

    You Searched For "Novartis"
    Novartis collaborates with Incyte with initiation plan of clinical study of Jakavi in COVID-19 patients

    Novartis collaborates with Incyte with initiation plan of clinical study of Jakavi in COVID-19 patients

    Medical Dialogues Bureau6 April 2020 9:54 AM GMT
    Basel: Novartis has announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib)...
    Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung

    Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung

    Medical Dialogues Bureau30 March 2020 7:49 AM GMT
    Zurich: Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit's malaria, lupus and arthritis drug hydroxychloroquine is the company's...
    Novartis, Life sciences companies commit to fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

    Novartis, Life sciences companies commit to fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

    Medical Dialogues Bureau29 March 2020 6:49 AM GMT
    Basel: Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture, and...
    Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy

    Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy

    Medical Dialogues Bureau22 March 2020 6:15 AM GMT
    Zolgensma is a one-time gene therapy designed to address the genetic root cause of the disease by replacing the function of the missing or nonworking...
    Novartis updates on uses and safety of Beovu in patients with wet AMD

    Novartis updates on uses and safety of Beovu in patients with wet AMD

    Medical Dialogues Bureau3 March 2020 4:30 AM GMT
    If clinical signs of intraocular inflammation or changes in vision after Beovu injection are observed doctor should perform the appropriate diagnostic...
    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Medical Dialogues Bureau29 Nov 2019 3:45 AM GMT
    Seventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab,...
    Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production

    Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production

    Medical Dialogues Bureau28 Nov 2019 3:30 AM GMT
    New Delhi: Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018,...
    Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal

    Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal

    Medical Dialogues Bureau26 Nov 2019 4:00 AM GMT
    In September 2018, the USD three billion drug-maker, Aurobindo Pharma said its US subsidiary entered into an agreement to acquire commercial...
    Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020

    Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020

    Medical Dialogues Bureau26 Nov 2019 3:58 AM GMT
    Roche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
    Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug

    Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug

    Medical Dialogues Bureau6 Nov 2019 5:02 AM GMT
    ZURICH: Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in...
    Another delay in USD 2.1 million gene therapy Zolgensma data reporting, Novartis admits mistake

    Another delay in USD 2.1 million gene therapy Zolgensma data reporting, Novartis admits mistake

    Medical Dialogues Bureau3 Nov 2019 4:15 AM GMT
    The USFDA on Wednesday placed a partial hold on a Novartis trial of the $2.1 million-per-patient gene therapy, Zolgensma after the company informed...
    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    Medical Dialogues Bureau31 Oct 2019 4:15 AM GMT
    Novartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X